Urinary bone resorption markers in patients with metabolic bone disorders

Area of Science:

• Biochemistry
• Endocrinology
• Bone Metabolism

Background:

• Urinary pyridinoline and deoxypyridinoline are established markers for assessing bone resorption.
• These markers are frequently evaluated in conditions characterized by altered bone turnover.

Purpose of the Study:

• To evaluate the efficacy of urinary pyridinoline and deoxypyridinoline as bone resorption markers.
• To compare their discriminatory ability against urinary hydroxyproline in hyperthyroidism, anticonvulsant drug therapy, and postmenopausal osteoporosis.

Main Methods:

• Analysis of urinary pyridinoline and deoxypyridinoline levels in patient cohorts (hyperthyroidism, anticonvulsant therapy, postmenopausal osteoporosis) and age-matched controls.
• Correlation analysis with urinary hydroxyproline.
• Receiver operating characteristic (ROC) curve analysis to determine marker discriminatory power.

Main Results:

• Both urinary pyridinoline and deoxypyridinoline showed significantly elevated levels in patient groups compared to controls.
• Strong correlations were observed between pyridinoline/deoxypyridinoline and hydroxyproline in hyperthyroidism.
• Pyridinoline demonstrated superior discriminatory ability compared to deoxypyridinoline in postmenopausal osteoporosis and anticonvulsant therapy groups when compared to hydroxyproline.

Conclusions:

• Urinary pyridinoline and deoxypyridinoline are reliable bone resorption markers.
• Pyridinoline exhibits better diagnostic performance than deoxypyridinoline in specific clinical contexts.
• These markers offer valuable insights into bone metabolism disturbances.